BioSpace News Archive

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, was recently named as a Top Company for Corporate Responsibility practices by both Newsweek and Investor’s Business Daily.

The Permanente Federation has appointed Todd M. Sachs, MD, to its National Permanente Leadership Team (NPLT) as executive vice president of Corporate Development and Finance.

If approved, Dupixent would be the first biologic medicine available in the U.S. for these children

Positive outlook for 2020: Sales revenue expected to rise 11% to 14% in constant currencies with further increase in profitability

Congratulations to Dr. Dattatreyudu Nori M.D., F.A.C.R, F.A.C.R.O, F.A.S.T.R.O for his new appointment as the International Director of Apollo Cancer Centers in India and South Asia.

Eko’s algorithms alert clinicians to the presence of heart murmurs and atrial fibrillation (AFib) during the physical exam, converting the classic stethoscope into a powerful early detection tool

Further Enhances the Commercial Value and Scale of Patient Centered Analytics

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), and Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that they have entered into a securities purchase agreement pursuant to which Innoviva will purchase,

The American Association of Orthodontists (AAO) - in the interests of the health, safety, and well-being of patients seeking orthodontic care - reports that on January 6, nine members of the U.S. House of Representatives authored a letter to the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) “to express [their] concern regarding SmileDirectClub.”

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, announced today that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the randomized, controlled, double-masked Phase 3 clinical trial